Evidence map›Paper›PMID 31107176›Full record

ArticlePopulation health management2020

Technology-Enabled Outreach to Patients Taking High-Risk Medications Reduces a Quality Gap in Completion of Clinical Laboratory Testing.

Marsha A Raebel, Susan M Shetterly, Bharati Bhardwaja, Andrew T Sterrett, Emily B Schroeder, Joseph Chorny, Tyson P Hagen, David J Silverman, Rex Astles, Ira M Lubin

Open access · greenAbstract read
In one paragraph

Article in Population health management, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Marsha A RaebelInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado.
Susan M ShetterlyInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado.
Bharati BhardwajaDepartment of Pharmacy, Kaiser Permanente Colorado, Denver, Colorado.
Andrew T SterrettInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado.
Emily B SchroederInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado.
Joseph ChornyRegional Laboratory, Colorado Permanente Medical Group, Denver, Colorado.
Tyson P HagenDepartment of Rheumatology, Colorado Permanente Medical Group, Lafayette, Colorado.
David J SilvermanDepartment of Rheumatology, Colorado Permanente Medical Group, Lafayette, Colorado.
Rex AstlesQuality and Safety Systems Branch, Division of Laboratory Systems, Centers for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, Georgia.
Ira M LubinQuality and Safety Systems Branch, Division of Laboratory Systems, Centers for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, Georgia.
Kaiser Permanente · USColorado Permanente Medical Group · USCenter for Surveillance, Epidemiology, and Laboratory Services · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Clinical laboratory quality improvement (QI) efforts can include population test utilization. The authors used a health care organization's Medical Data Warehouse (MDW) to characterize a gap in guideline-concordant laboratory testing recommended for safe use of antirheumatic agents, then tested the effectiveness of laboratory-led, technology-enabled outreach to patients at reducing this gap. Data linkages available through the Kaiser Permanente Colorado MDW and electronic health record were used to identify ambulatory adults taking antirheumatic agents who were due/overdue for alanine aminotransferase (ALT), aspartate aminotransferase (AST), complete blood count (CBC), or serum creatinine (SCr) testing. Outreach was implemented using an interactive voice response system to send patients text or phone call reminders. Interrupted time series analysis was used to estimate reminder effectiveness. Rates of guideline-concordant testing and testing timeliness in baseline vs. intervention periods were determined using generalized linear models for repeated measures. Results revealed a decrease in percentage of 3763 patients taking antirheumatic agents due/overdue for testing at any given time: baseline 24.3% vs. intervention 17.5% (

Indexed as

Drug MonitoringQuality ImprovementReminder SystemsAdultAgedAged, 80 and overAntirheumatic AgentsArthritis, RheumatoidClinical Laboratory TechniquesElectronic Health RecordsFemaleHealth CommunicationHumansMaleMiddle AgedText MessagingAntirheumatic Agentsantirheumatic agentsclinical laboratorydata linkagedata warehouseinteractive voice responsepopulation managementquality improvement

Identifiers

PMID31107176
PMCPMC6954341
OpenAlexW2946431751

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.